Vertex delivers tax technology software and SaaS solutions to corporations seeking streamlined compliance and integration ...

Vertex Pharmaceuticals surged in premarket trading after its kidney disease drug povetacicept met the main goal in a late-stage trial.

Abstract: In artificial spin ice (ASI) systems, where fabricated magnetic nanoislands meet at vertices, domain wall (DW) motion through these vertices plays a crucial role in determining the overall ...

Hughes to lead hyperscale data center operations, business development, and training across Vertex’s fastest-growing ...

Cystic fibrosis (CF) specialist Vertex is tracking two newer launches that speak to its efforts to expand its prowess beyond those roots. Despite mixed early results for those rollouts so far, the ...

Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia ...

Vertex has delivered earnings growth over the past decade thanks to its leadership in cystic fibrosis treatment. In recent years, the company has launched products in other treatment areas too. On top ...

Vertex Pharmaceuticals is downgraded to Hold ahead of Q4 earnings due to underwhelming growth from key new drugs. Journavx and Casgevy sales remain niche, raising doubts about their ability to drive ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex executives warned that Casgevy, its ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial ...